Like far too many of us, the life of Gregory Lubiniecki, M.D., was forever changed by his family's struggle with cancer in the early years of his life. While many facing such a challenge can feel overwhelmed with helplessness, Lubiniecki saw the experience as a call to action; his loved ones inspired him to enter the field of medicine and pursue a career in medical oncology.
Pleural and Lung Cancer
Excellence in Research
10+ Years of Experience
Board Certified in Medical Oncology
Board Certified in Internal Medicine
Board Certified in Hematology
After completing his medical training at Johns Hopkins University in 1998, Lubiniecki spent his residency studying internal medicine at Mayo Graduate School of Medicine. He went on to work as a medical oncologist at the Clinical Practices of the University of Pennsylvania before joining the Fox Chase Cancer Center in 2009.
A National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Fox Chase is nationally recognized for its leadership in medical, radiation and surgical oncology. Here, Lubiniecki draws on his clinical expertise in mesothelioma and lung cancer to provide cancer patients with quality diagnosis, treatment and palliative care.
Lubiniecki takes a personalized, multidisciplinary approach to treatment. This means he and a diverse team of cancer specialists and health care team members work closely with each patient to meet his or her individual needs. He stresses the importance of effective communication between the doctor and patient, as well as between all the members of the patient’s care team.
Get help connecting with Dr. Lubiniecki and find the treatment that's best for you.Get Help Now
Marquis Who’s Who has included Dr. Lubiniecki in publications for Emerging Leaders, Medicine and Healthcare, Science Engineering and Who’s Who in America.
Mesothelioma treatment begins with an accurate diagnosis. After the cancer is located with advanced imaging techniques or biopsy, Lubiniecki then identifies the tumor’s defining characteristics. This helps determine how the cancer will respond to different chemotherapy drugs. Further, this approach helps Lubiniecki and his team improve future treatments by pinpointing the tumor types that are resistant to specific drugs or a combination of several.
In addition to treating mesothelioma and lung cancer, Lubiniecki is also an active researcher. He strives to offer only the latest treatment options with the highest chance of success and minimal side effects.
Disclaimer: Dr. Gregory Lubiniecki has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.
View our resources for patients and familiesGet Help Today